048IC - Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

Course Description: This is a repeat course with a continuing need. Taught by a mix of MDs and APPs, the target audience spans the spectrum of practitioners and trainees in urologic oncology. The speakers focus on advanced and metastatic prostate, kidney, and bladder cancers. The talks are didactic with some personal experience and cases interwoven. Updated NCCN guidelines are incorporated into each tumor type and the speakers highlight the studies and trials that helped to shape these guidelines. At the end of the talks, if there is time after questions, representative cases are presented and the speakers become panelists discussing management.

Learning Objective 1: Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.

Learning Objective 2: Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy.

Learning Objective 3: Diagram the treatment options for high-risk non-muscle invasive bladder cancer.

Learning Objective 4: Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer.

Learning Objective 5: Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy.